In a phase III trial, pembrolizumab improved overall survival in patients with recurrent or metastatic head and neck squamous cell carcinoma.
In a phase III trial, pembrolizumab improved overall survival in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Input your search keywords and press Enter.